<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755376</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2013-07-117-002</org_study_id>
    <nct_id>NCT02755376</nct_id>
  </id_info>
  <brief_title>Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell</brief_title>
  <official_title>A Randomized, Single Center, Investigator Initiated Clinical Trial to Evaluate Enhancement of Healing Between Bone Tunnel and Graft in Anterior Cruciate Ligament (ACL) Injury Using Human Umbilical Cord Blood Derived Mesenchymal Stem Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:Development of novel strategy for treatment of anterior cruciate ligament (ACL)
      injury using stem cell.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose: Development of novel strategy for treatment of anterior cruciate ligament (ACL)
           injury using stem cell.

        2. Subject: Anterior cruciate ligament (ACL) injury 30 patients

             -  ACL reconstruction: 10

             -  ACL reconstruction + Human cord blood derived mesenchymal stem cells and hyaluronic
                acid (Cartistem (TM)): 10

             -  ACL reconstruction + hyaluronic acid: 10

        3. Hypothesis: Human Cord blood derived mesenchymal stem cells can enhance healing between
           bone tunnel and graft in ACL reconstruction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone formation on interface between bone tunnel and graft</measure>
    <time_frame>Changes at 12 week, 24 week, 48 week after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arthroscopic grading of graft</measure>
    <time_frame>48 week after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telos stress X-ray</measure>
    <time_frame>Changes at 12 week, 24 week, 48 week after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KT-2000</measure>
    <time_frame>Changes at 12 week, 24 week, 48 week after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical knee scoring</measure>
    <time_frame>Changes at 12 week, 24 week, 48 week after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instability assessing with physical examination</measure>
    <time_frame>Changes at 12 week, 24 week, 48 week after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tunnel enlargement after anterior cruciate ligament reconstruction</measure>
    <time_frame>Changes at 12 week, 24 week, 48 week after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Deficiency of Anterior Cruciate Ligament</condition>
  <arm_group>
    <arm_group_label>ACL reconstruction only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>only ACL reconstruction without any injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACL reconstruction + Cartistem(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACL reconstruction + Hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cartistem(TM)</intervention_name>
    <description>ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.</description>
    <arm_group_label>ACL reconstruction + Cartistem(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hyaluronic acid</intervention_name>
    <description>ACL reconstruction and injection of hyaluronic acid under arthroscopy.</description>
    <arm_group_label>ACL reconstruction + Hyaluronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ACL reconstruction only</intervention_name>
    <description>ACL reconstruction only without any injection under arthroscopy</description>
    <arm_group_label>ACL reconstruction only</arm_group_label>
    <arm_group_label>ACL reconstruction + Cartistem(TM)</arm_group_label>
    <arm_group_label>ACL reconstruction + Hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20~50

          2. Lachman test grade II,III or Pivot shift test grade I,II,III or ACL rupture in MRI

          3. prothrombin time (PT) (INR) &lt;1.5, activated partial thromboplastin time (aPTT) &lt;1.5 x
             control

          4. Creatinine ≤2.0 ㎎/㎗, protein uria(dipstick) ≤ trace

          5. Bilirubin ≤2.0 ㎎/㎗, aspartate aminotransferase (AST) /Alanine Aminotransferase (ALT)
             ≤100 IU/L

          6. No surgery and radiation therapy in recent 6 weeks

          7. No pregnancy

          8. No combine ligament instability ≥ grade II in physical examination (grade 0: none,
             grade I: 0~5mm, grade II: 5~10mm, grade III: &gt;10mm)

          9. voluntary singed a consent form

        Exclusion Criteria:

          1. Degenerative osteoarthritis in knee

          2. Revision or other surgery history (stem cell treatment)

          3. Chronic inflammatory joint disease like rheumatoid arthritis

          4. Infectious disease need to administration of parenteral antibiotics

          5. Autoimmune disease

          6. Myocardial infarction, congestive heart failure, other serious heart disease

          7. Uncontrolled hypertension

          8. Serious medical disease

          9. Pregnancy and breast-feeding

         10. psychiatric disorder and epilepsy

         11. Alcohol overuse

         12. Smoking overuse

         13. Administration of immunosuppressive agents like Cyclosporin A or Azathioprine in
             recent 6 weeks prior screening test

         14. Patient participating in other clinical trials in recent 4 weeks

         15. Combined ligament instability ≥ grade II in physical test.

         16. No allergy history to gentamicin antibiotics

         17. Hypersensitivity patient to bovine protein, hyaluronic acid, and anesthetic agent

         18. Inappropriate patient judged by researcher.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joon Ho Wang, MD, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gang-nam gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>age, physical exam, lab, etc will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

